Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life

Dr. Patel asks how supportive care demands, quality of life, and financial and time toxicities shape shared decision-making in frontline EGFR-mutated non-small cell lung cancer (NSCLC), and whether subcutaneous amivantamab has changed his colleague's risk-benefit assessment. Dr. Doroshow argues quality of life, time, and financial toxicity cannot be separated from efficacy, because efficacy is determined in a trial vacuum while effectiveness depends on whether patients can actually receive and tolerate the medicine.

On subcutaneous amivantamab, Dr. Doroshow notes it reduces infusion-related reactions, but FDA-recommended monitoring times remain substantial. She references data from World Lung 2024 (Florez et al.) suggesting time toxicity may not be significantly reduced when those recommendations are followed, though she expects observation periods to shorten with experience. At her institution, patients receiving the first IV amivantamab dose are essentially there all day. Dr. Patel agrees subcutaneous amivantamab is the standard at UC San Diego and is, in his view, a different drug from the patient-experience standpoint.

On the COCOON regimen for cutaneous toxicity prophylaxis, Dr. Doroshow flags that asking patients to layer multiple topicals plus an oral antibiotic is itself time-toxic, and that adherence can be challenging for patients who do not speak English. She emphasizes nurse-reinforced education and refers severe rashes to her oncodermatologist. Dr. Patel agrees prevention is the best treatment, sees patients weekly during the first month for early intervention, and notes dose reduction and brief treatment holds maintain quality of life over a long treatment course.

In the next episode, "Sequential planning and how the chessboard shapes frontline choice," Dr. Patel asks how anticipated next-line options factor into upfront regimen selection.een FLAURA2 and MARIPOSA, Dr. Doroshow explains that no single feature pulls her toward one regimen. She references an individual patient–level analysis suggesting a possible advantage for FLAURA2 in patients with CNS metastases and for MARIPOSA in TP53-mutant tumors but says she is more often influenced by toxicity profiles and patient preference. She still favors osimertinib monotherapy for patients with borderline performance status, those declining combination therapy, or those with logistical barriers such as living far from the hospital.